As a new type of foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has built a "1+2+3+4=1" service system and can supply bile acid raw materials from multiple well-known original manufacturers.
As a foreign trade enterprise with R&D capabilities, HiSiaddi has conducted multiple rounds of field inspections of bile acid manufacturers based on extensive industry resources, developing objective and in-depth understanding of different brands. We regularly analyze various bile acid manufacturers for clients to help them select products matching their production needs. Below is a brand matching recommendation case.
If you require cross-brand model comparison and analysis, please contact HiSiaddi customer service.
The client is Nordic Pharma, a renowned high-end pharmaceutical enterprise headquartered in Norway. It specializes in hepatobiliary API, prescription formulations and premium dietary supplements sold at high-end pharmacies and public hospitals across Norway, Sweden and Finland, complying with EP, USP, EU GMP and REACH regulations. The client planned long-term procurement of pharmaceutical-grade ursodeoxycholic acid (UDCA) for mass production of self-developed hepatoprotective oral formulations.
As an overseas mid-to-high-end purchaser with deep expertise in end-product R&D, the client lacked understanding of China’s leading bile acid manufacturers, their flagship product models, performance differences and applicable scenarios. It previously contacted 4 mainstream domestic manufacturers, each of which only promoted its own products without maliciously slandering competitors yet avoided objective comparisons of rival strengths, weaknesses and applicability. Without horizontal reference data on parameters, processes, delivery and supporting services, the client could not finalize supplier selection and faced stalled procurement progress. The client entrusted HiSiaddi with neutral evaluation of mainstream domestic brands and flagship models, screening mid-to-high-end brands and specific models aligned with its production requirements to complete bulk procurement.
1. Core procurement demands Purchase pharmaceutical-grade UDCA meeting rigid standards: purity ≥99.8%, total impurities ≤0.2%, low endotoxin, complete sets of EU/US compliance documentation and stable large-volume supply. Products must adapt to oral formulation production lines while balancing cost performance and long-term supply stability.
2. Existing challenges
· Blank brand awareness: Unfamiliar with positioning, technical routes and production capacity of China’s leading bile acid manufacturers, unable to distinguish high-end medical-grade products from ordinary industrial-grade variants.
· One-sided information: Contacted manufacturers only highlight their own advantages without disclosing weaknesses or introducing competitor features, lacking data for horizontal comparison.
· Confusion over model differentiation: Different models under the same brand vary in purity, impurity control and applicable scenarios, making precise matching with production lines impossible for the client.
· Subsequent risk concerns: Fear of quality non-compliance, incomplete documentation and delayed delivery if selecting inappropriate brands/models, disrupting formulation mass production.
Drawing on industry resources, quality inspection data and overseas supply cases, HiSiaddi screened 5 mainstream domestic bile acid manufacturers and conducted neutral comparative analysis across seven dimensions: flagship models, core product indicators, technical processes, strengths, weaknesses, applicable scenarios and overseas service capabilities, presenting balanced pros and cons without bias toward any manufacturer.
Flagship models: UDCA-01 (Pharmacopoeia Standard Grade), UDCA-02 (Ultra-High Purity Medical Special Grade) Core parameters: UDCA-01 achieves 99.8% purity compliant with EP/USP standards; UDCA-02 reaches ≥99.9% purity with ultra-low isomer and heavy metal residues. Core strengths: Domestic leader in UDCA production with large production capacity, nearly 20 years of experience serving overseas pharmaceutical markets and abundant EU client cases. Complete compliance documentation system provides one-stop English COAs, pharmacopoeia certifications, animal-free certificates and REACH registration materials with highly stable batch consistency via mature processes. Weaknesses: Premium pricing for ultra-high-purity models with limited flexibility for small-batch customization. Applicable scenarios: Long-term bulk procurement by large pharmaceutical enterprises, premium prescription formulations and raw material exports to EU pharmaceutical markets.
Flagship models: General-Grade CDCA, Medical Standard UDCA Core parameters: Purity ranges from 99.7%–99.8% with compliant impurity limits, positioned as cost-effective pharmaceutical-grade raw materials. Core strengths: Specializes in bile acid extraction and synthesis focusing on conventional pharmaceutical-grade products with ample production capacity, short lead times and large spot inventories for standard models, plus responsive basic after-sales support. Weaknesses: Limited capacity for ultra-high-purity customization; less refined high-end compliance documentation with limited experience supporting high-end EU audits. Applicable scenarios: Mid-tier formulations, conventional dietary supplements and bulk procurement prioritizing cost performance.
Flagship models: BA-C03 (Compound Bile Acid), Medical & Cosmetic UDCA Core parameters: Purity 99.6%–99.8%, featuring modified products with superior solubility and compound compatibility. Core strengths: Outstanding technical expertise in formulation adaptation and product modification, expanding into premium cosmetic raw materials alongside pharmaceutical applications with excellent compound stability and capacity for basic formulation debugging support for clients. Weaknesses: Limited range of pure pharmaceutical-grade UDCA products with less extensive large-scale API export experience compared to specialized pharmaceutical raw material manufacturers. Applicable scenarios: Pharmaceutical compound formulations, premium skincare products and applications requiring optimized dissolution performance.
Flagship model: Sterile Pharmaceutical-Grade UDCA Core parameters: Purity ≥99.85% with stringent endotoxin control meeting pre-injection grade standards and rigorous sterile management systems. Core strengths: Listed large pharmaceutical enterprise operating under strict GMP standards with sterile workshop production, suitable for injectables and high-grade sterile formulations. Complete traceability systems passing regulatory audits worldwide. Weaknesses: Production capacity prioritized for domestic key clients leading to extended foreign trade scheduling and longer lead times for standard models with mid-to-high overall pricing. Applicable scenarios: Sterile formulations, injectable pharmaceuticals and premium products with extreme microbial/endotoxin control requirements.
Flagship models: General Pharmaceutical-Grade UDCA, Sodium Cholate Series Core parameters: Purity approximately 99.5%, suitable for basic pharmaceutical intermediates and conventional formulations. Core strengths: Diverse complete product portfolio with clear price advantages focused on basic raw material markets. Weaknesses: Mid-to-low market positioning lacking ultra-high-purity and low-impurity models; incomplete high-end EU compliance documentation unsuitable for export premium prescription formulations. Applicable scenarios: Basic pharmaceutical intermediates, ordinary health supplements and non-export formulations.
First-round elimination: The client produces premium Nordic prescription formulations with strict purity, compliance and audit standards, eliminating Hubei Tuoyuan (low-end positioning) and Shandong Jiangzheng (insufficient high-end compliance capacity), retaining three mid-to-high-end brands: Zhongshan Bailing, Shandong Longchang Hesheng and Zhejiang Hisun.
Second-round precise matching: The client focuses on oral hepatoprotective formulations without injectable sterile requirements, alongside demands for stable long-term supply, complete EU documentation and reasonable cost: Zhejiang Hisun’s sterile standards exceed client needs with extended lead times and higher costs, so it is eliminated. Two preferred brands remain: Zhongshan Bailing Bio and Shandong Longchang Hesheng.
Combining the client’s core demands of oral formulation mass production, long-term bulk procurement and balanced quality-cost performance, clear model selection recommendations were issued with tailored advantages highlighted for each variant:
Model 1: UDCA-01 Pharmacopoeia Standard Grade Matching rationale: 99.8% purity fully compliant with EP/USP pharmacopoeia, consistent batch quality, mature EU export track record, complete compliance documentation and stable lead times, perfectly suited for the client’s mass production of core oral formulations as the primary procurement model. Model 2: UDCA-02 Ultra-High Purity Medical Special Grade Matching rationale: ≥99.9% purity with minimal impurities, recommended as an alternative for new product R&D and premium upgraded formulations.
Model 3: Medical & Cosmetic UDCA Matching rationale: 99.8% purity with modified optimization delivering superior solubility and formulation compatibility, applicable to the client’s compound dietary supplement portfolio and serving as backup raw material supply to mitigate supply disruption risks.
Sample delivery and testing: HiSiaddi coordinated free sample delivery of the three recommended models from both manufacturers. The client completed full-spec laboratory testing and formulation bench trials, confirming all three models met specifications with Bailing UDCA-01 demonstrating optimal compatibility with existing production lines. Documentation verification: Collated English COAs, certification documents, traceability files and audit materials for all three models, all passing preliminary Nordic regulatory reviews. Commercial and production capacity confirmation: Assisted the client in negotiating pricing, payment terms, annual supply volumes and quality compensation clauses with manufacturers to finalize long-term cooperation frameworks. Bulk order delivery: The client designated Zhongshan Bailing UDCA-01 as its core procurement model with an initial 20-ton order, supplemented by Longchang Hesheng model stock as backup. Goods were packed per EU standards with complete customs clearance and compliance documentation for smooth delivery to the client’s factory.
1. Resolution of brand selection challenges Through HiSiaddi’s neutral cross-brand model analysis, the client clearly differentiated product performance across manufacturers, breaking information monopolies from individual suppliers and accurately selecting raw materials matching its product specifications.
2. Successful procurement implementation The initial 20-ton bile acid shipment was delivered on schedule with fully compliant quality and documentation, enabling smooth mass production on the client’s manufacturing lines.
3. Long-term cooperation established The client signed a 60-ton annual framework procurement agreement with Zhongshan Bailing, listing Longchang Hesheng as a backup supplier to establish dual-source supply security. All raw material sourcing for subsequent new product R&D continues to entrust HiSiaddi with brand evaluation and procurement services.
Client Feedback: "HiSiaddi maintained neutrality across all manufacturers, delivering comprehensive cross-brand analysis that saved us substantial trial and error. The precisely matched products fully comply with Nordic high-end pharmaceutical standards, making them a reliable long-term partner for procurement services."
Overseas mid-to-high-end pharmaceutical enterprises purchasing bile acids commonly lack familiarity with China’s domestic brand landscape and are limited to one-sided information from individual suppliers, leading to biased procurement judgments.
In this case, leveraging accumulated industry experience, HiSiaddi adhered to neutrality to conduct horizontal comparative analysis of mainstream domestic manufacturers covering technology, products, services and applicable scenarios. Two rounds of screening aligned with the client’s premium formulation requirements identified two mid-to-high-end brands and three precisely matched models. This helped the client avoid low-grade products and mismatched performance while balancing quality, compliance and supply stability to complete efficient model selection and procurement. Dual-supplier systems were established to mitigate supply disruption risks, fully satisfying long-term procurement demands of mid-to-high-end overseas clients.
If you require cross-brand model comparison and analysis, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
